公开(公告)号：US10357552B2

公开(公告)日：2019-07-23

申请号：US16054561

申请日：2018-08-03

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Colette Song

IPC: A61K39/00 ,  G16B25/00 ,  A61K35/17 ,  C07K16/18 ,  C12N5/0783 ,  C12N15/115 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C07K14/47 ,  A61K35/12 ,  C07K14/705

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10335471B2

公开(公告)日：2019-07-02

申请号：US15249083

申请日：2016-08-26

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  C12N15/115 ,  C07K7/06 ,  C07K7/08 ,  C07K14/725 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10314896B2

公开(公告)日：2019-06-11

申请号：US16106951

申请日：2018-08-21

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  G16B25/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/725 ,  C07K14/71 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/115 ,  C07K16/18 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K14/705 ,  C07K16/40 ,  C12N9/02 ,  C07K14/81 ,  C07K16/38 ,  C12N9/12 ,  C07K14/72 ,  A61K38/00 ,  A61K35/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10293036B2

公开(公告)日：2019-05-21

申请号：US15436385

申请日：2017-02-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Oliver Schoor ,  Andrea Mahr ,  Toni Weinschenk ,  Anita Wiebe ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190119351A1

公开(公告)日：2019-04-25

申请号：US16227228

申请日：2018-12-20

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fristsche ,  Harpreet Singh ,  Lea Stevermann

IPC: C07K14/74 ,  G01N33/569 ,  A61K38/06 ,  C12N9/64 ,  C12N5/0783 ,  C07K16/30 ,  C07K14/47 ,  A61K39/00 ,  C07K16/28 ,  A61K45/06 ,  C07K14/00 ,  C07K7/06 ,  C07K7/02 ,  G01N33/50 ,  G01N33/566 ,  C07K16/18 ,  A61K38/08 ,  C07K14/725 ,  A61K38/17 ,  C12Q1/6886

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10253076B2

公开(公告)日：2019-04-09

申请号：US15199066

申请日：2016-06-30

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18 ,  A61K38/00 ,  A61K35/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190076514A1

公开(公告)日：2019-03-14

申请号：US16193334

申请日：2018-11-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Oliver Schoor ,  Andrea Mahr ,  Toni Weinschenk ,  Anita Wiebe ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/30 ,  C07K2319/33 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57492

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US10202437B2

公开(公告)日：2019-02-12

申请号：US16009330

申请日：2018-06-15

Applicant: immatics biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/74 ,  C07K16/28 ,  A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/635 ,  C07K14/47 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190040114A1

公开(公告)日：2019-02-07

申请号：US16165275

申请日：2018-10-19

Applicant: Immatics Biotechnologies GmbH

Inventor： Annika Sonntag ,  Toni Weinschenk ,  Andrea Mahr ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/74 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00 ,  C12N5/0783 ,  C07K14/725 ,  G06F19/20 ,  A61K38/17 ,  C12Q1/6886 ,  A61K35/17 ,  C12N15/115

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K38/04 ,  A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61P35/00 ,  A61P37/04 ,  C07K7/06 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/70539 ,  G16B25/00

Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

公开(公告)号：US20190030075A1

公开(公告)日：2019-01-31

申请号：US16162337

申请日：2018-10-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni Weinschenk ,  Anita Wiebe ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/47 ,  C12N5/0783 ,  C07K16/30 ,  A61K39/00 ,  C07K14/74 ,  C07K16/18 ,  C12N15/115

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.